Ind-Swift Ltd Competitors & Peer Comparison
Pharmaceuticals · Indian listed companies
Compare Ind-Swift Ltd with 125 companies shown from the same industry classification, including Denis Chem Lab Ltd, Fervent Synergies Ltd, Concord Drugs Ltd. These are industry peers; their products, customers and business models may differ.
Selected-company price and ratio data: . Peer reporting dates can differ. Stored figures, not live quotes.
Compare valuation, size and returns
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Ind-Swift Ltd | 85.4 Cr. | 15.8 | / | 10.9 | 74.2 | 0.00 % | 11.9 % | % | 2.00 |
| Denis Chem Lab Ltd | 93.5 Cr. | 67.4 | 97.4/56.1 | 11.7 | 66.0 | 3.71 % | 14.0 % | 9.52 % | 10.0 |
| Fervent Synergies Ltd | 73.3 Cr. | 14.7 | 26.0/13.0 | 20.1 | 11.4 | 0.00 % | 7.21 % | 7.22 % | 10.0 |
| Concord Drugs Ltd | 99.7 Cr. | 75.7 | 92.5/61.0 | 48.9 | 36.8 | 0.00 % | 5.19 % | 2.52 % | 10.0 |
| Pharmaids Pharmaceuticals Ltd | 106 Cr. | 30.2 | 60.0/25.6 | 13.5 | 0.00 % | 18.5 % | 26.5 % | 10.0 | |
| Vaishali Pharma Ltd | 109 Cr. | 8.38 | 11.9/4.75 | 25.8 | 5.29 | 0.00 % | 8.93 % | 6.02 % | 2.00 |
| Cian Healthcare Ltd | 61.2 Cr. | 24.5 | 24.5/4.72 | 3.42 | 0.00 % | 15.1 % | 49.2 % | 10.0 | |
| ANG Lifesciences India Ltd | 52.5 Cr. | 40.2 | 49.7/17.6 | 47.6 | 0.00 % | 1.14 % | 7.38 % | 10.0 | |
| Vivimed Labs Ltd | 48.2 Cr. | 5.71 | 29.4/4.75 | 25.4 | 0.00 % | 65.2 % | % | 2.00 | |
| Biofil Chemicals & Pharmaceuticals Ltd | 47.8 Cr. | 29.3 | 46.8/25.6 | 99.6 | 13.2 | 0.00 % | 2.97 % | 2.83 % | 10.0 |
| Mangalam Drugs and Organics Ltd | 46.2 Cr. | 29.2 | 74.0/22.7 | 65.3 | 0.00 % | 14.0 % | 34.8 % | 10.0 | |
| Alpa Laboratories Ltd | 125 Cr. | 59.3 | 99.8/46.0 | 28.5 | 93.4 | 0.00 % | 8.91 % | 7.90 % | 10.0 |
| Godavari Drugs Ltd | 129 Cr. | 118 | 135/69.7 | 33.1 | 74.8 | 0.00 % | 6.55 % | 6.14 % | 10.0 |
| Bacil Pharma Ltd | 39.2 Cr. | 27.3 | 61.8/10.6 | 60.2 | 17.3 | 0.00 % | 3.93 % | 6.21 % | 10.0 |
| Murae Organisor Ltd | 38.8 Cr. | 0.19 | 0.55/0.19 | 2.56 | 1.02 | 0.00 % | 4.20 % | 5.69 % | 1.00 |
| Lactose (India) Ltd | 133 Cr. | 105 | 136/76.0 | 19.1 | 51.5 | 0.00 % | 11.3 % | 9.81 % | 10.0 |
| Chandra Bhagat Pharma Ltd | 37.3 Cr. | 49.4 | 53.0/29.7 | 12.2 | 43.9 | 0.00 % | 12.1 % | 9.67 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 134 Cr. | 9.18 | 14.3/1.96 | 44.8 | 0.81 | 0.00 % | 22.9 % | 16.6 % | 1.00 |
| Bharat Immunological & Biological Corporation Ltd | 35.3 Cr. | 8.18 | 22.6/8.16 | 18.2 | 0.00 % | 9.27 % | 17.7 % | 10.0 | |
| Achyut Healthcare Ltd | 143 Cr. | 5.91 | 10.0/4.70 | 446 | 1.45 | 0.00 % | 1.18 % | 0.96 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 27.4 Cr. | 35.2 | 59.8/29.0 | 12.3 | 12.5 | 0.00 % | 39.2 % | 30.2 % | 10.0 |
| Krebs Biochemicals & Industries Ltd | 146 Cr. | 68.0 | 76.8/38.3 | 75.5 | 0.00 % | 15.4 % | % | 10.0 | |
| Auro Laboratories Ltd | 152 Cr. | 244 | 317/159 | 31.7 | 74.4 | 0.00 % | 9.52 % | 8.49 % | 10.0 |
| Par Drugs & Chemicals Ltd | 153 Cr. | 124 | 180/78.0 | 10.5 | 91.0 | 0.00 % | 14.6 % | 9.95 % | 10.0 |
| Checkpoint Trends Ltd | 17.4 Cr. | 31.9 | 144/28.4 | 14.2 | 42.5 | 0.00 % | 15.0 % | 12.7 % | 10.0 |
| Ortin Laboratories Ltd | 16.4 Cr. | 20.1 | 26.4/16.2 | 3.47 | 0.00 % | 60.2 % | 118 % | 10.0 | |
| Desh Rakshak Aushdhalaya Ltd | 15.3 Cr. | 26.9 | 59.6/22.4 | 27.9 | 23.3 | 0.00 % | 7.50 % | 5.59 % | 10.0 |
| Beryl Drugs Ltd | 12.8 Cr. | 25.3 | 27.6/15.9 | 20.7 | 19.5 | 0.00 % | 7.25 % | 4.34 % | 10.0 |
| Chemo Pharma Laboratories Ltd | 11.8 Cr. | 79.0 | 153/70.0 | 8.60 | 0.00 % | 0.28 % | 0.28 % | 10.0 | |
| Dipna Pharmachem Ltd | 10.9 Cr. | 4.15 | 25.0/3.90 | 4.15 | 23.7 | 0.00 % | 7.64 % | 5.22 % | 10.0 |
| Colinz Laboratories Ltd | 9.26 Cr. | 73.5 | 87.9/36.1 | 18.5 | 39.9 | 0.00 % | 7.20 % | 5.23 % | 10.0 |
| Brooks Laboratories Ltd | 162 Cr. | 54.8 | 138/36.3 | 12.3 | 41.6 | 0.00 % | 21.2 % | 22.0 % | 10.0 |
| Adline Chem Lab Ltd | 8.80 Cr. | 15.0 | 17.1/7.60 | 3.03 | 0.00 % | 1,267 % | % | 10.0 | |
| Ganga Pharmaceuticals Ltd | 7.39 Cr. | 12.5 | 14.0/9.35 | 73.9 | 14.1 | 0.00 % | 2.90 % | 1.30 % | 10.0 |
| Brawn Biotech Ltd | 7.38 Cr. | 24.6 | 24.7/17.7 | 8.68 | 14.5 | 0.00 % | 0.00 % | 24.4 % | 10.0 |
| Decipher Labs Ltd | 6.06 Cr. | 6.00 | 11.0/5.00 | 20.5 | 0.00 % | 16.7 % | 14.2 % | 10.0 | |
| Amerise Biosciences Ltd | 5.15 Cr. | 0.78 | 1.03/0.50 | 0.82 | 0.00 % | 0.37 % | 0.37 % | 1.00 | |
| Fabino Enterprises Ltd | 4.27 Cr. | 20.3 | 27.0/13.0 | 18.7 | 0.00 % | 6.22 % | 8.76 % | 10.0 | |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 2.08/1.57 | 0.04 | 0.00 % | 13.1 % | 177 % | 10.0 | |
| Evoq Remedies Ltd | 3.79 Cr. | 1.52 | 6.11/1.35 | 17.8 | 0.00 % | 0.56 % | 0.54 % | 10.0 | |
| Bal Pharma Ltd | 169 Cr. | 106 | 125/59.7 | 23.4 | 51.6 | 1.13 % | 9.69 % | 7.87 % | 10.0 |
| Coral Laboratories Ltd | 196 Cr. | 549 | 679/360 | 10.3 | 585 | 0.36 % | 11.0 % | 7.79 % | 10.0 |
| Nectar Lifescience Ltd | 202 Cr. | 10.2 | 22.5/9.20 | 30.0 | 0.00 % | 0.05 % | 31.3 % | 1.00 | |
| Ambalal Sarabhai Enterprises Ltd | 203 Cr. | 26.5 | 42.0/23.1 | 11.4 | 19.2 | 0.00 % | 9.12 % | 6.25 % | 10.0 |
| Everest Organics Ltd | 219 Cr. | 220 | 536/197 | 41.7 | 77.7 | 0.00 % | 12.0 % | 7.63 % | 10.0 |
| Gennex Laboratories Ltd | 238 Cr. | 9.80 | 17.2/7.05 | 12.7 | 9.16 | 0.00 % | 11.8 % | 10.5 % | 1.00 |
| BDH Industries Ltd | 278 Cr. | 482 | 610/340 | 23.7 | 134 | 1.04 % | 20.5 % | 14.8 % | 10.0 |
| Lyka Labs Ltd | 292 Cr. | 81.6 | 105/44.1 | 25.9 | 0.00 % | 5.98 % | 10.2 % | 10.0 | |
| Aarey Drugs & Pharmaceuticals Ltd | 321 Cr. | 104 | 108/50.3 | 77.1 | 53.0 | 0.00 % | 5.58 % | 2.75 % | 10.0 |
| SMS Lifesciences India Ltd | 357 Cr. | 1,197 | 1,680/956 | 20.6 | 650 | 0.13 % | 11.8 % | 10.8 % | 10.0 |
| Albert David Ltd | 489 Cr. | 857 | 932/580 | 21.7 | 686 | 0.58 % | 0.82 % | 0.44 % | 10.0 |
| Wanbury Ltd | 694 Cr. | 198 | 360/162 | 16.2 | 18.1 | 0.00 % | 36.6 % | 76.5 % | 10.0 |
| Kilitch Drugs (India) Ltd | 760 Cr. | 219 | 234/117 | 25.3 | 80.0 | 0.00 % | 13.4 % | 10.6 % | 10.0 |
| Anuh Pharma Ltd | 857 Cr. | 85.8 | 99.5/66.7 | 19.4 | 35.1 | 1.75 % | 14.9 % | 10.7 % | 5.00 |
| Bafna Pharmaceuticals Ltd | 881 Cr. | 379 | 385/94.8 | 113 | 40.6 | 0.00 % | 11.9 % | 12.3 % | 10.0 |
| Themis Medicare Ltd | 1,038 Cr. | 113 | 147/65.0 | 43.3 | 0.44 % | 2.74 % | 0.41 % | 1.00 | |
| Lincoln Pharmaceuticals Ltd | 1,167 Cr. | 582 | 770/440 | 12.1 | 378 | 0.31 % | 16.3 % | 12.3 % | 10.0 |
| Kopran Ltd | 1,364 Cr. | 282 | 296/107 | 54.6 | 110 | 1.06 % | 6.65 % | 4.91 % | 10.0 |
| TTK Healthcare Ltd | 1,438 Cr. | 1,013 | 1,250/735 | 18.8 | 789 | 0.99 % | 8.04 % | 6.30 % | 10.0 |
| Amrutanjan Health Care Ltd | 1,485 Cr. | 513 | 760/476 | 23.9 | 128 | 0.95 % | 24.8 % | 18.4 % | 1.00 |
| Jagsonpal Pharmaceuticals Ltd | 1,533 Cr. | 232 | 265/155 | 32.6 | 41.2 | 1.73 % | 22.7 % | 17.3 % | 2.00 |
| Fermenta Biotech Ltd | 1,628 Cr. | 553 | 580/249 | 29.8 | 138 | 0.68 % | 20.6 % | 16.4 % | 5.00 |
| Hester Biosciences Ltd | 1,810 Cr. | 2,127 | 2,684/1,239 | 34.1 | 423 | 0.52 % | 15.2 % | 15.9 % | 10.0 |
| Panacea Biotec Ltd | 2,203 Cr. | 359 | 648/292 | 136 | 0.00 % | 2.43 % | 2.42 % | 1.00 | |
| Fredun Pharmaceuticals Ltd | 2,238 Cr. | 1,355 | 1,600/427 | 50.3 | 170 | 0.02 % | 21.5 % | 15.8 % | 10.0 |
| Syncom Formulations (India) Ltd | 2,240 Cr. | 24.0 | 27.5/10.2 | 26.4 | 4.39 | 0.42 % | 24.8 % | 17.6 % | 1.00 |
| Beta Drugs Ltd | 2,298 Cr. | 2,073 | 2,808/990 | 50.4 | 241 | 0.00 % | 19.2 % | 18.8 % | 10.0 |
| Indoco Remedies Ltd | 2,311 Cr. | 252 | 317/162 | 102 | 0.08 % | 0.96 % | 9.36 % | 2.00 | |
| Dishman Carbogen Amcis Ltd | 2,365 Cr. | 150 | 307/128 | 130 | 426 | 0.00 % | 3.14 % | 1.58 % | 2.00 |
| Venus Remedies Ltd | 2,401 Cr. | 1,797 | 2,044/432 | 20.7 | 497 | 0.56 % | 20.7 % | 15.6 % | 10.0 |
| Hikal Ltd | 2,691 Cr. | 218 | 261/146 | 63.5 | 97.2 | 0.28 % | 3.50 % | 2.21 % | 2.00 |
| Advanced Enzyme Technologies Ltd | 3,080 Cr. | 274 | 420/252 | 19.6 | 146 | 1.95 % | 14.0 % | 10.2 % | 2.00 |
| Ind-Swift Laboratories Ltd | 3,456 Cr. | 395 | 425/87.0 | 53.1 | 159 | 0.00 % | 4.86 % | 4.02 % | 10.0 |
| Solara Active Pharma Sciences Ltd | 3,472 Cr. | 715 | 774/422 | 813 | 346 | 0.00 % | 4.86 % | 0.13 % | 10.0 |
| Kwality Pharmaceuticals Ltd | 3,704 Cr. | 3,564 | 3,949/829 | 45.4 | 321 | 0.00 % | 23.9 % | 22.5 % | 10.0 |
| Unichem Laboratories Ltd | 3,761 Cr. | 535 | 687/278 | 30.8 | 386 | 0.00 % | 4.13 % | 3.17 % | 2.00 |
| Aarti Drugs Limited | 3,846 Cr. | 421 | 534/319 | 22.2 | 154 | 0.48 % | 11.7 % | 12.7 % | 10.0 |
| Gufic BioSciences Ltd | 4,198 Cr. | 418 | 468/268 | 57.1 | 66.2 | 0.02 % | 12.2 % | 9.98 % | 1.00 |
| Zota Health Care Ltd | 4,391 Cr. | 1,268 | 1,740/1,022 | 200 | 0.08 % | 8.47 % | 15.0 % | 10.0 | |
| SMS Pharmaceuticals Ltd | 4,403 Cr. | 471 | 494/253 | 48.6 | 85.9 | 0.08 % | 12.9 % | 11.9 % | 1.00 |
| RPG Life Sciences Ltd | 4,848 Cr. | 2,931 | 3,130/1,731 | 41.6 | 366 | 0.82 % | 25.7 % | 19.3 % | 8.00 |
| Gujarat Themis Biosyn Ltd | 4,967 Cr. | 382 | 479/225 | 102 | 26.4 | 0.18 % | 18.1 % | 17.4 % | 1.00 |
| FDC Ltd | 5,463 Cr. | 336 | 476/313 | 17.7 | 153 | 1.49 % | 15.4 % | 11.2 % | 1.00 |
| Orchid Pharma Ltd | 5,935 Cr. | 990 | 1,144/471 | 329 | 300 | 0.00 % | 1.86 % | 1.49 % | 10.0 |
| IOL Chemicals & Pharmaceuticals Ltd | 6,143 Cr. | 209 | 219/67.1 | 34.8 | 61.3 | 0.48 % | 11.3 % | 8.42 % | 2.00 |
| Sanofi India Ltd | 6,991 Cr. | 3,037 | 4,898/3,000 | 20.4 | 359 | 2.47 % | 57.5 % | 43.0 % | 10.0 |
| Bliss GVS Pharma Ltd | 7,259 Cr. | 684 | 745/118 | 52.8 | 113 | 0.22 % | 16.9 % | 11.8 % | 1.00 |
| Entero Healthcare Solutions Ltd | 7,308 Cr. | 1,681 | 1,920/944 | 56.6 | 388 | 0.00 % | 10.5 % | 6.94 % | 10.0 |
| Morepen Laboratories Ltd | 7,327 Cr. | 134 | 135/33.0 | 62.4 | 22.8 | 0.15 % | 8.05 % | 5.33 % | 2.00 |
| Suven Life Sciences Ltd | 8,717 Cr. | 308 | 403/124 | 22.4 | 0.00 % | 79.5 % | 81.5 % | 1.00 | |
| Sequent Scientific Ltd | 8,768 Cr. | 201 | 260/111 | 203 | 32.2 | 0.00 % | 8.47 % | 3.21 % | 2.00 |
| Aarti Pharmalabs Ltd | 8,796 Cr. | 968 | 1,002/584 | 40.9 | 234 | 0.36 % | 10.7 % | 8.59 % | 5.00 |
| Procter & Gamble Health Ltd | 8,900 Cr. | 5,360 | 6,975/4,700 | 26.7 | 316 | 2.89 % | 83.9 % | 61.9 % | 10.0 |
| Blue Jet Healthcare Ltd | 10,241 Cr. | 542 | 693/325 | 43.6 | 78.4 | 0.22 % | 26.1 % | 19.4 % | 2.00 |
| Concord Biotech Ltd | 14,377 Cr. | 1,374 | 1,648/987 | 50.6 | 193 | 0.55 % | 17.4 % | 12.6 % | 1.00 |
| Marksans Pharma Ltd | 14,757 Cr. | 326 | 351/155 | 28.6 | 66.7 | 0.28 % | 18.8 % | 15.2 % | 1.00 |
| Natco Pharma Ltd | 14,844 Cr. | 821 | 1,217/786 | 13.0 | 470 | 0.61 % | 17.4 % | 17.1 % | 2.00 |
| Astrazeneca Pharma India Ltd | 15,071 Cr. | 6,031 | 9,850/5,978 | 86.9 | 349 | 0.60 % | 29.3 % | 23.3 % | 2.00 |
| Jubilant Pharmova Ltd | 15,918 Cr. | 999 | 1,185/784 | 41.0 | 445 | 0.50 % | 8.99 % | 6.53 % | 1.00 |
| Alembic Pharmaceuticals Ltd | 16,010 Cr. | 815 | 998/635 | 21.5 | 289 | 1.47 % | 12.6 % | 13.4 % | 2.00 |
| ERIS Lifesciences Ltd | 16,532 Cr. | 1,190 | 1,740/1,163 | 25.2 | 282 | 0.61 % | 14.1 % | 18.7 % | 1.00 |
| Cohance Lifesciences Ltd | 17,259 Cr. | 451 | 918/267 | 160 | 102 | 0.00 % | 5.81 % | 4.89 % | 1.00 |
| Pfizer Ltd | 17,652 Cr. | 3,859 | 5,578/3,792 | 23.0 | 919 | 1.94 % | 24.1 % | 18.0 % | 10.0 |
| Caplin Point Laboratories Ltd | 20,062 Cr. | 2,632 | 2,991/1,500 | 30.2 | 443 | 0.30 % | 24.2 % | 20.9 % | 2.00 |
| Shilpa Medicare Ltd | 20,841 Cr. | 1,064 | 1,096/260 | 73.3 | 132 | 0.06 % | 10.9 % | 8.99 % | 1.00 |
| Granules India Ltd | 22,395 Cr. | 822 | 924/520 | 34.4 | 205 | 0.21 % | 15.5 % | 13.8 % | 1.00 |
| Acutaas Chemicals Ltd | 26,172 Cr. | 3,196 | 3,740/1,373 | 67.8 | 202 | 0.08 % | 31.6 % | 24.0 % | 5.00 |
| Neuland Laboratories Ltd | 27,536 Cr. | 21,505 | 24,235/11,500 | 55.3 | 1,461 | 0.16 % | 26.5 % | 21.2 % | 10.0 |
| Wockhardt Ltd | 33,875 Cr. | 2,084 | 2,422/1,087 | 85.0 | 304 | 0.00 % | 7.55 % | 6.11 % | 5.00 |
| J B Chemicals & Pharmaceuticals Ltd | 38,677 Cr. | 2,409 | 2,526/1,603 | 53.8 | 259 | 0.91 % | 25.4 % | 18.9 % | 1.00 |
| Ajanta Pharma Ltd | 44,789 Cr. | 3,581 | 3,797/2,379 | 39.5 | 362 | 0.89 % | 34.5 % | 27.1 % | 2.00 |
| Glaxosmithkline Pharmaceuticals Ltd | 46,973 Cr. | 2,771 | 3,121/2,088 | 44.6 | 134 | 2.06 % | 61.4 % | 45.6 % | 10.0 |
| Gland Pharma Ltd | 47,356 Cr. | 2,874 | 3,042/1,574 | 33.5 | 656 | 0.70 % | 17.4 % | 12.8 % | 1.00 |
| Ipca Laboratories Ltd | 49,292 Cr. | 1,943 | 2,039/1,252 | 35.9 | 318 | 0.31 % | 17.0 % | 15.7 % | 1.00 |
| Abbott India Ltd | 56,984 Cr. | 26,840 | 30,655/25,135 | 35.3 | 2,247 | 1.96 % | 44.8 % | 34.4 % | 10.0 |
| Biocon Ltd | 60,299 Cr. | 371 | 447/338 | 82.9 | 210 | 0.13 % | 3.61 % | 1.40 % | 5.00 |
| Alkem Laboratories Ltd | 62,625 Cr. | 5,220 | 5,934/5,051 | 27.6 | 1,156 | 1.02 % | 21.2 % | 18.9 % | 2.00 |
| Glenmark Life Sciences Ltd | 66,493 Cr. | 2,331 | 2,538/1,793 | 21.3 | 372 | 0.21 % | 39.8 % | 23.6 % | 1.00 |
| Glenmark Pharmaceuticals Ltd | 66,493 Cr. | 2,331 | 2,538/1,793 | 21.3 | 372 | 0.21 % | 39.8 % | 23.6 % | 1.00 |
| Lupin Ltd | 92,348 Cr. | 2,031 | 2,530/1,900 | 15.5 | 491 | 0.89 % | 29.9 % | 28.7 % | 2.00 |
| Aurobindo Pharma Ltd | 96,798 Cr. | 1,677 | 1,740/1,066 | 25.6 | 652 | 0.24 % | 12.9 % | 10.1 % | 1.00 |
| Dr Reddys Laboratories Ltd | 1,00,435 Cr. | 1,206 | 1,415/1,080 | 31.2 | 454 | 0.66 % | 13.0 % | 11.2 % | 1.00 |
| Mankind Pharma Ltd | 1,04,657 Cr. | 2,535 | 2,642/1,910 | 46.3 | 397 | 0.04 % | 13.7 % | 13.8 % | 1.00 |
| Laurus Labs Ltd | 1,07,111 Cr. | 1,984 | 2,055/843 | 123 | 97.3 | 0.10 % | 16.0 % | 15.2 % | 2.00 |
| Cipla Ltd | 1,08,256 Cr. | 1,344 | 1,673/1,166 | 30.2 | 426 | 0.97 % | 15.5 % | 11.6 % | 2.00 |
| Torrent Pharmaceuticals Ltd | 1,81,276 Cr. | 4,767 | 5,250/3,480 | 81.2 | 248 | 0.80 % | 15.2 % | 27.4 % | 5.00 |
| Industry Average | 17,560.90 Cr | 1,250.16 | 54.88 | 211.24 | 0.39% | 26.16% | 16.59% | 6.06 |
How to use this peer comparison
Start with similar company sizes, then compare P/E with ROCE and ROE. A lower P/E alone does not establish better value. Negative earnings, unusual items, debt and different reporting dates can make ratios unsuitable for direct comparison.
The company list is ordered by market-cap proximity to Ind-Swift Ltd, with P/E as a secondary comparison. The industry-average row uses available stored values across the industry, which can include companies beyond the rows shown. Missing values are not zero.
Open each company report for financial statements and its cited sources. Industry classifications indicate a research peer group, not a verified list of direct commercial competitors.
Read the full Ind-Swift Ltd analysis · Explore all Pharmaceuticals stocks